162 results
Page 2 of 9
6-K
ruyg li0vta4
11 Sep 23
Current report (foreign)
6:50am
6-K
EX-99.1
vtz9m
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
mn09zug 5lkg1i
6 Jul 23
Current report (foreign)
6:18am
6-K
cobk 3nqpfearm
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
movg3xbb5irp 323
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
ou23lw48lmgqd7o
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
fjzn rbmxhc
30 May 23
Current report (foreign)
6:11am
6-K
kg38rt9hkpvx rd445
17 May 23
Current report (foreign)
6:02am
6-K
9f5564q7nk5ga
11 May 23
Current report (foreign)
6:10am
6-K
lwchd
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
4ymhs3wek2n gzu
11 May 23
Current report (foreign)
6:07am
6-K
29k3x6sfu 43q
30 Mar 23
Current report (foreign)
6:19am
6-K
EX-99.1
u8iwa
21 Dec 22
Current report (foreign)
6:01am
6-K
ifb0ilk7
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
90fm3v958meyc
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
lz6xytduqp5h5t
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
ya7o3xktuyycqk7dic
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
rj4f9umt6c c8d
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
aub3m3 xncd
27 Oct 22
Current report (foreign)
6:01am